Timothy Ragsdale, MD
Otolaryngology · Bedford, TXNPI 1205829959
Payments from drug & device makers
Across 58 payments — averaging $128.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerin Medical Inc.$3K
- Acclarent, Inc$2K
- Medical Device Business Services, Inc.$834
- Inspire Medical Systems, Inc.$176
- Neurent Medical Limited$172
- Intersect ENT, Inc.$121
- plus $423 from 12 others
What the payments were for
- Consulting fees$3,66349%
- Speaking & faculty fees$1,55021%
- Travel & lodging$6268%
- Food & beverage$1,63322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerin Medical Inc. | 7 | $3,377 |
| Acclarent, Inc | 12 | $2,367 |
| Medical Device Business Services, Inc. | 9 | $834 |
| Inspire Medical Systems, Inc. | 2 | $176 |
| Neurent Medical Limited | 8 | $172 |
| Intersect ENT, Inc. | 1 | $121 |
| Medtronic | 3 | $85 |
| GSK | 4 | $69 |
| Sanofi | 1 | $35 |
| Optinose US, Inc. | 2 | $33 |
| Stryker | 1 | $31 |
| Integra Lifesciences Corporation | 1 | $31 |
| Smith+Nephew | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Olympus America Inc. | 1 | $25 |
| Spirair, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACCLARENT Balloon Inflation Device$2,063
- VIVAER STYLUS$1,661
- RHINAER STYLUS$1,661
- VivAer$1,600
- RhinAer$1,600
- Inspire$147
- PROPEL$121
How this compares
$7,472 in reported general payments places this provider in the 80th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 371 | $9,399 |
| Azelastine Hcl | 219 | $8,066 |
| Fluticasone Propionate | 108 | $2,028 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 14 | $1,615 |
| CefuroximeCefuroxime Axetil | 37 | $742 |
| Nortriptyline Hcl | 31 | $674 |
| Gabapentin | 39 | $658 |
| Omeprazole | 32 | $427 |
| Montelukast Sodium | 65 | $383 |
| Tramadol Hcl | 29 | $105 |
| Levothyroxine Sodium | 19 | $98 |
| Prednisone | 48 | $96 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Bedford
- Laurence ChuAustin$37.4M
- Mark ZafereoHouston$7.8M
- Neil GrossHouston$1.5M
- Chad McDuffieFrisco$1.5M
- Ian AlexanderBoerne$999K
- Stephen LaiHouston$968K
- Benjamin CilentoSpring$963K
- Amber LuongHouston$793K
- Jeffrey RosenbloomSan Antonio$720K
- Masayoshi TakashimaHouston$644K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.